CS Capital, a private equity investment firm, led a $50m Series B round in InxMed, a clinical-stage biotech company, with participation from AIHC Fund, Growth Fund, Hosencare Fund, and Ennovation Venture. "InxMed is focused on the development of innovative treatments to address the true global unmet medical needs. Our strategy is targeting the ecosystem fostered by tumor cells including tumor microenvironment to develop effective therapeutic regimens to combat or even cure cancer. We have built robust pipelines with different, yet complementary Mechanism of Actions. Building partnership is also our important strategy to maximize the value of our assets, and we are actively exploring global partnership opportunities to accelerate more value inflections of IN10018 and other programs," Zaiqi Wang, InxMed Founder and Chief Executive Officer.